找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Clinical Pharmacology: Current Topics and Case Studies; Markus Müller Book 2016Latest edition Springer International Publishing Switzerlan

[復制鏈接]
樓主: 厭倦了我
41#
發(fā)表于 2025-3-28 16:02:43 | 只看該作者
Margareta Stefanovic,Michael G. Safonovand that “drug therapy varies widely among individuals” [.]. These two statements set the stage for the discipline of clinical pharmacology (CP) which pursues two main goals: (1) an empirical description of conditions under which drug actions vary in humans and (2) to determine and understand the mo
42#
發(fā)表于 2025-3-28 20:33:58 | 只看該作者
Margareta Stefanovic,Michael G. Safonoves, most notably infections, have extremely satisfying therapeutic success rates, and many serious diseases like diabetes mellitus or some forms of cancer have become chronic, stable diseases and do not lead to extreme shortages of life years any longer. Prime examples for success stories in drug de
43#
發(fā)表于 2025-3-29 00:38:09 | 只看該作者
44#
發(fā)表于 2025-3-29 04:27:29 | 只看該作者
45#
發(fā)表于 2025-3-29 09:45:47 | 只看該作者
46#
發(fā)表于 2025-3-29 14:01:19 | 只看該作者
Ken Chan,Clive Fencott,Barry Hebbronessively establish their safety and ultimately their efficacy. Disasters occur only rarely during phase I trials, which have a remarkable safety record. In 2006, a contract research organization was conducting the first human testing of TGN1412 an immunomodulatory anti-CD28 monoclonal antibody. All
47#
發(fā)表于 2025-3-29 19:36:42 | 只看該作者
48#
發(fā)表于 2025-3-29 20:30:31 | 只看該作者
49#
發(fā)表于 2025-3-30 03:06:15 | 只看該作者
50#
發(fā)表于 2025-3-30 07:34:57 | 只看該作者
Legal Aspects of Safety Critical Systemse the number of compounds where the pharmacokinetics observed at a microdose compared to a therapeutic dose has grown steadily. Based upon the most up-to-date review at the time of writing (2013, reference Lappin et al., Expert Opin Drug Metab Toxicol 9(7):817–834, 2013), there are 35 compounds wher
 關于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結 SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-21 23:34
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權所有 All rights reserved
快速回復 返回頂部 返回列表
民和| 城口县| 新闻| 河池市| 庄河市| 镇巴县| 北票市| 武隆县| 南雄市| 黄骅市| 桂阳县| 盖州市| 安多县| 海丰县| 建昌县| 东莞市| 武定县| 缙云县| 仁化县| 军事| 稷山县| 英山县| 昌黎县| 永顺县| 手机| 宁波市| 富顺县| 河津市| 长葛市| 临城县| 伊金霍洛旗| 文成县| 美姑县| 延边| 鹤庆县| SHOW| 南郑县| 晋州市| 泰兴市| 德保县| 潼关县|